Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gilead Goes For The Gold (Standard) In Plan To Acquire HCV Specialist Pharmasset

This article was originally published in The Pink Sheet Daily

Executive Summary

The planned purchase price of $11 billion, or $137 a share, an 89% premium over Pharmasset’s closing price on Nov. 18, is by far the highest ever paid for a clinical-stage biotech.

You may also be interested in...

Stockwatch: Gilead, BMS Expose High Cost Of M&A

Expensive acquisitions are in the spotlight during earnings season. The purchases of Kite and Celgene by Gilead and Bristol-Myers Squibb are not turning out to be what was written on the tin.

The Cost Of A Cure: Gilead Exec Outlines Factors In Sovaldi’s Pricing

Gilead Science Executive VP Gregg Alton defended Sovaldi’s pricing at an AEI event July 11, the same day Senators Wyden and Grassley sent a letter requesting detailed information on the company’s investment in the drug and how it set the price.

It’s “Full Speed Ahead” For Merck In HCV After $3.85B Idenix Buyout

The company expects to come charging out of the gate with a three-drug combo therapy for hepatitis C now that it has acquired a nucleotide analog to round out its portfolio. Merck is undeterred by the risks associated with the deal.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts